Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Mitoxantrone + GDP in R/R PTCL
NCT05441761Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma (PTCL), sponsored by Peking Union Medical College Hospital. Primary endpoints: Recommended Phase II Dose at 1 year and Objective Response Rate at 3 years. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05441761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441761.